Your session is about to expire
← Back to Search
Pembrolizumab + T-DM1 for Breast Cancer
Study Summary
This trial is studying how well the combination of pembrolizumab and trastuzumab emtansine works in treating patients with breast cancer that has spread to other parts of the body.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2024 Phase 2 trial • 57 Patients • NCT03004183Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am not taking strong CYP3A4 inhibitors while on T-DM1 treatment.I am on long-term steroids or other drugs that weaken my immune system.Your heart's pumping ability must be normal, as checked by a heart ultrasound or MUGA scan within 28 days before starting the study drug.I have moderate to severe nerve damage.I have brain metastases that are either untreated, causing symptoms, or need treatment for symptoms.You have a current infection of Hepatitis B or Hepatitis C.You have HIV.The bone abnormalities cannot be accurately measured.I have had radiation therapy before, either for early-stage or advanced cancer.My disease can be measured or evaluated in the current study phase.I am currently taking bisphosphonates and can continue them during the study.I have not had another type of cancer, or if I did, it meets certain conditions.I have an autoimmune disease that needs steroids or other immune-suppressing drugs.My breast cancer is confirmed and has spread to other parts of my body.My organ and bone marrow functions are normal.I have a tumor that can be measured and hasn't been previously radiated.I have a history of lung inflammation not caused by an infection.You are allergic to pembrolizumab or T-DM1 or any of the substances used to make them.My breast cancer is HER2 positive according to the 2013 guidelines.I have not received a live vaccine in the last 28 days.I can take care of myself but might not be able to do active work.My last chemotherapy was over 3 weeks ago.I have been diagnosed with cancer that has spread to the lining of my brain and spinal cord.I have never been treated with T-DM1.I finished my radiation therapy at least 14 days ago.I do not have any uncontrolled illnesses like high blood pressure or heart problems.I stopped all experimental or biologic treatments 3 weeks ago.I have been treated with trastuzumab and a taxane before.I am not on IV antibiotics for an infection as of the first day of treatment.I have previously been treated with pembrolizumab or similar therapies.I've had one treatment for my spreading breast cancer or it came back within 6 months after my last treatment.I am 18 years old or older.
- Group 1: Pembrolizumab Combine With Trastuzumab Emtansine
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are enrollment opportunities for this research project available now?
"Unfortunately, this study has now ended its recruitment phase. Its initial post was made on February 17th 2017 and the last update to it occurred on July 25th 2022. However, if you are still seeking clinical trials related to breast cancer there are presently 2,600 studies actively recruiting patients and 999 for Pembrolizumab alone."
To what maladies has Pembrolizumab been employed to offer relief?
"Pembrolizumab is commonly employed to tackle cancerous neoplasms, but it can also be used for treating advanced melanoma cases, those with high levels of microsatellite instability, and for responding inadequately to chemotherapy."
Has this type of experiment been performed before?
"Pembrolizumab was initially studied back in 2008, with Hoffmann-La Roche sponsoring the first trial which included 720 patients. After Phase 2 drug approval had been granted, it has since become an active research subject in 68 countries and 3281 cities - currently featuring 999 studies."
What precedent literature exists on the efficacy of Pembrolizumab?
"At the current moment, over 999 clinical trials are running related to Pembrolizumab. Of those studies, 131 have entered Phase 3. Primarily based in Rochester, Minnesota, data from 41689 locations offer insight into this drug's performance."
Could you elucidate the potential risks of Pembrolizumab for participants?
"The safety standings of Pembrolizumab is classified as a 1, due to the limited amount of clinical data that supports both its efficacy and potential hazards."
How many participants are being accepted into this clinical trial?
"As of the last update on July 25th 2022, this clinical trial is no longer seeking participants. However, if you are looking for alternative trials there are 2,600 studies involving breast cancer and 999 studies utilizing pembrolizumab with open recruitment."
Share this study with friends
Copy Link
Messenger